UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance

Oncogene, 2017-03, Vol.36 (11), p.1537-1545

2017

Volltextzugriff (PDF)

Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance

Oncogene, 2017-11, Vol.36 (46), p.6508-6508

2017

Volltextzugriff (PDF)

CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer

International journal of gynecological cancer, 2003-03, Vol.13 (2), p.120-124

2003

Volltextzugriff (PDF)

PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death

Cell death and differentiation, 2012-09, Vol.19 (9), p.1549-1560

2012

Volltextzugriff (PDF)

Genetic Counseling and Testing in Ovarian Cancer From the Patient Perspective

Gynecologic oncology, 2016-10, Vol.143 (1), p.220-220

2016

Volltextzugriff (PDF)

Nitric Oxide is an Important Mediator for Tumoricidal Activity In vivo

Proceedings of the National Academy of Sciences - PNAS, 1994-09, Vol.91 (20), p.9407-9411

1994

Volltextzugriff (PDF)

FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival

International journal of gynecological cancer, 2002-09, Vol.12 (5), p.454-458

2002

Volltextzugriff (PDF)

Characterization of serum biomarkers for detection of early stage ovarian cancer

Proteomics (Weinheim), 2005-11, Vol.5 (17), p.4589-4596

2005

Volltextzugriff (PDF)

Differential Effects of Prostaglandin Derived from ω-6 and ω-3 Polyunsaturated Fatty Acids on COX-2 Expression and IL-6 Secretion

Proceedings of the National Academy of Sciences - PNAS, 2003-02, Vol.100 (4), p.1751-1756

2003

Volltextzugriff (PDF)

Understanding Health Disparities in Preeclampsia: A Literature Review

American journal of perinatology, 2024-05, Vol.41 (S 01), p.e1291-e1300

2024

Volltextzugriff (PDF)

Reversal of the Hypomethylation Status of Urokinase (uPA) Promoter Blocks Breast Cancer Growth and Metastasis

The Journal of biological chemistry, 2004-07, Vol.279 (30), p.31735-31744

2004

Volltextzugriff (PDF)

Before and after GOG 99: Did our practice patterns for treatment of intermediate risk endometrial adenocarcinoma change?

Gynecologic oncology, 2010-03, Vol.116 (3), p.595-595

2010

Volltextzugriff (PDF)

Identification of Biomarkers for Ovarian Cancer Using Strong Anion-Exchange ProteinChips: Potential Use in Diagnosis and Prognosis

Proceedings of the National Academy of Sciences - PNAS, 2003-10, Vol.100 (21), p.12343-12348

2003

Volltextzugriff (PDF)

ApoA1: A Putative Target for Early Stage Ovarian Cancer Therapy

Gynecologic oncology, 2007-11, Vol.107 (2), p.364-364

2007

Volltextzugriff (PDF)

Urokinase Plasminogen Activator Receptor: Prognostic Biomarker for Endometrial Cancer

Proceedings of the National Academy of Sciences - PNAS, 2002-08, Vol.99 (16), p.10647-10652

2002

Volltextzugriff (PDF)

Erratum: Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance

Oncogene, 2017-11, Vol.36 (46), p.6508-6508

2017

Volltextzugriff (PDF)

CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer

International journal of gynecological cancer, 2003-02, Vol.13 (2), p.120-124

2003

Volltextzugriff (PDF)

The Chemistry and Tumoricidal Activity of Nitric Oxide/Hydrogen Peroxide and the Implications to Cell Resistance/Susceptibility

The Journal of biological chemistry, 1996-03, Vol.271 (11), p.6144-6151

1996

Volltextzugriff (PDF)

Solitary Recurrent Metastasis of Epithelial Ovarian Cancer in the Spleen

Gynecologic oncology, 1993-03, Vol.48 (3), p.338-341

1993

Volltextzugriff (PDF)

992O - FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

Annals of oncology, 2019-10, Vol.30, p.v403-v403

2019

Volltextzugriff (PDF)

992OFORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

Annals of oncology, 2019-10, Vol.30, p.v403

2019

Volltextzugriff (PDF)

FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival

International journal of gynecological cancer, 2002-08, Vol.12 (5), p.454-458

2002

Volltextzugriff (PDF)

The Urokinase Plasminogen Activator Receptor (UPAR) Is Preferentially Induced by Nerve Growth Factor in PC12 Pheochromocytoma Cells and Is Required for NGF-Driven Differentiation

The Journal of neuroscience, 2000-01, Vol.20 (1), p.230-239

2000

Volltextzugriff (PDF)

The importance of communication between the pathologist and the clinician in caring for patients receiving gynecologic treatment

American journal of clinical pathology, 1995-04, Vol.103 (4 Suppl 1), p.S13-S16

1995

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(51)
Tagungsberichte
(1)

Sprache

Englisch
(52)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance

Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance

CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer

PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death

Genetic Counseling and Testing in Ovarian Cancer From the Patient Perspective

Nitric Oxide is an Important Mediator for Tumoricidal Activity In vivo

FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival

Characterization of serum biomarkers for detection of early stage ovarian cancer

Differential Effects of Prostaglandin Derived from ω-6 and ω-3 Polyunsaturated Fatty Acids on COX-2 Expression and IL-6 Secretion

Understanding Health Disparities in Preeclampsia: A Literature Review

Reversal of the Hypomethylation Status of Urokinase (uPA) Promoter Blocks Breast Cancer Growth and Metastasis

Before and after GOG 99: Did our practice patterns for treatment of intermediate risk endometrial adenocarcinoma change?

Identification of Biomarkers for Ovarian Cancer Using Strong Anion-Exchange ProteinChips: Potential Use in Diagnosis and Prognosis

ApoA1: A Putative Target for Early Stage Ovarian Cancer Therapy

Urokinase Plasminogen Activator Receptor: Prognostic Biomarker for Endometrial Cancer

Erratum: Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance

CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer

The Chemistry and Tumoricidal Activity of Nitric Oxide/Hydrogen Peroxide and the Implications to Cell Resistance/Susceptibility

Solitary Recurrent Metastasis of Epithelial Ovarian Cancer in the Spleen

992O - FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

992OFORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival

The Urokinase Plasminogen Activator Receptor (UPAR) Is Preferentially Induced by Nerve Growth Factor in PC12 Pheochromocytoma Cells and Is Required for NGF-Driven Differentiation

The importance of communication between the pathologist and the clinician in caring for patients receiving gynecologic treatment

Suchergebnisse filtern